Immune response in asymptomatic and immunocompromised

Abstract

SARS (severe acute respiratory syndrome) is the severe stage of COVID-19 caused by massive alveolar damage and progressive respiratory failure; caused by SARS-CoV-2. As of August 17, 2022, SARS-CoV-2 has infected 174,954,240 people in the Americas region; 2,814,403 have died; Europe is the continent with the highest number of cases (1,013,093), in Ecuador, with 975,234 confirmed cases and 35.81 deaths, with the highest number of infected in the province of Pichincha with 165,854 confirmed cases and Guayas with 65,886 confirmed cases. The objective of this study is to determine the immune response in asymptomatic and immunocompromised patients. Materials and methods; a review of scientific articles was carried out and they were selected based on the topic, the proposed topics, published in English and Spanish, of all ages, in a period of time from 2017 - 2022, were included in the attached article search engines; Scielo, Elsevier, Redalyc, Dialnet and Medigraphic. In conclusion; the COVID 19 pandemic spread through human-human transmission, and, although the virus identifies ACE2 receptors in epithelial cells of various organs, it is possible that there are increases in antibody-dependent infections (ADEs).